The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Bamalite     2-[[3-methyl-4-(2,2,2- trifluoroethoxy)pyri...

Synonyms: Lansopep, Lasoprol, Limpidex, Mesactol, PrevOnco, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lanproton


Psychiatry related information on Lanproton

  • AIM: To perform a randomized, double-blind, placebo-controlled trial of a single dose of lansoprazole (30 mg) taken prior to a large meal and alcohol consumption [5].
  • The eradication rate of H. pylori was 93% (95% CI, 76-99%) in the quadruple therapy group, 83% (95% CI, 64-94%) in the dual therapy group, 100% (95% CI, 87-100%) in the triple therapy group, and 0% (95% CI, 0-12%) in the lansoprazole and placebo group [6].
  • Triple therapy containing lansoprazole 30 mg once daily, AM 500 mg and CM 250 mg twice daily for two weeks is a promising regimen which reaches a high eradication rate, avoids MZ resistance, and has very good patient compliance at an acceptable cost [7].

High impact information on Lanproton

  • Lansoprazole, 30 mg twice daily, produced symptom resolution, and repeat ambulatory pH showed complete acid suppression in the proximal esophagus [8].
  • CONCLUSIONS: H. pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole [2].
  • INTERVENTION: Patients were randomly assigned to a treatment group (n = 17), which received a proton-pump inhibitor (omeprazole or lansoprazole), amoxicillin, and either clarithromycin or ecabet sodium, or to a control group (n = 18), which received no treatment [9].
  • H2 receptor antagonists had no significant effect (P > .2) over the entire range of concentration tested, whereas omeprazole and lansoprazole significantly inhibited the rate of DNA synthesis by 60% to 90% at 30 mumol/L (P = .016) [10].
  • We conclude that, in contrast to H2 receptor antagonists, omeprazole and lansoprazole are able to interfere with the replicative synthesis of DNA in human hepatocytes in culture, at suprapharmacological concentrations [10].

Chemical compound and disease context of Lanproton


Biological context of Lanproton

  • OBJECTIVE: We investigated the pharmacokinetics, pharmacodynamics, and tolerability of lansoprazole in children after single and multiple administrations [16].
  • Plasma lansoprazole levels in patients with the homozygous extensive metabolizer genotype were the lowest of the 3 groups [17].
  • The pharmacokinetics of lansoprazole were significantly different among groups; AUC values were 1.55+/-0.20 microg x h/mL in white extensive metabolizers, 7.01+/-0.72 microg x hr/mL in Korean extensive metabolizers, and 14.34+/-2.60 microg x h/mL in poor metabolizers (P < .001) [18].
  • OBJECTIVE: To evaluate the enantioselective disposition of lansoprazole in relation to the genetic polymorphism of CYP2C19 [19].
  • CONCLUSIONS: These results suggest that the hydroxylation of lansoprazole cosegregates with the genetically determined S-mephenytoin 4'-hydroxylation (CYP2C19) polymorphism in the Korean subjects [20].

Anatomical context of Lanproton


Associations of Lanproton with other chemical compounds


Gene context of Lanproton

  • As a result, PMs of CYP2C19 experience more effective acid suppression and better healing of duodenal and gastric ulcers during treatment with omeprazole and lansoprazole compared with EMs [29].
  • Antibodies against rat CYP3A enzymes inhibited the rate of both 5-hydroxylation (approximately 55%) and sulfoxidation (approximately 70%) and cDNA-expressed CYP3A4 catalyzed both the 5-hydroxylation and sulfoxidation of lansoprazole (apparent Km approximately 100 microM) [30].
  • Identification of the human P450 enzymes involved in lansoprazole metabolism [30].
  • Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture [31].
  • The cDNA expressed enzymes CYP2C8, CYP2C9 and CYP2C19 catalyzed varying rates of lansoprazole 5-hydroxylation at a substrate concentration of 50 microM, but only CYPC19 catalyzed this reaction at 1 microM [30].

Analytical, diagnostic and therapeutic context of Lanproton


  1. Activity of lansoprazole against Helicobacter pylori. Megraud, F., Boyanova, L., Lamouliatte, H. Lancet (1991) [Pubmed]
  2. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Eissele, R., Brunner, G., Simon, B., Solcia, E., Arnold, R. Gastroenterology (1997) [Pubmed]
  3. Lansoprazole, H. pylori, and atrophic gastritis. Kuipers, E.J., Klinkenberg-Knol, E.C., Festen, H.P., Meuwissen, S.G. Gastroenterology (1997) [Pubmed]
  4. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Robinson, M., Lanza, F., Avner, D., Haber, M. Ann. Intern. Med. (1996) [Pubmed]
  5. The prophylactic use of a proton pump inhibitor before food and alcohol. O'Leary, C., McCarthy, J., Humphries, M., Shanahan, F., Quigley, E. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  6. Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Arkkila, P.E., Seppälä, K., Kosunen, T.U., Sipponen, P., Mäkinen, J., Rautelin, H., Färkkilä, M. European journal of gastroenterology & hepatology. (2005) [Pubmed]
  7. A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. Yang, J.C., Yang, K.C., Hsu, C.T., Wang, C.S., Kuo, C.F., Wang, T.H. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. (1999) [Pubmed]
  8. Acid secretion from an esophageal inlet patch demonstrated by ambulatory pH monitoring. Galan, A.R., Katzka, D.A., Castell, D.O. Gastroenterology (1998) [Pubmed]
  9. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ohkusa, T., Takashimizu, I., Fujiki, K., Suzuki, S., Shimoi, K., Horiuchi, T., Sakurazawa, T., Ariake, K., Ishii, K., Kumagai, J., Tanizawa, T. Ann. Intern. Med. (1998) [Pubmed]
  10. Effect of anti-ulcer drugs on DNA synthesis in adult normal human hepatocytes in culture. Blanc, P., Liautard, J., Greuet, J., Daures, J.P., Fabre, J.M., Larrey, D., Michel, H., Maurel, P. Hepatology (1995) [Pubmed]
  11. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Nelson, W.W., Vermeulen, L.C., Geurkink, E.A., Ehlert, D.A., Reichelderfer, M. Arch. Intern. Med. (2000) [Pubmed]
  12. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Agrawal, N.M., Campbell, D.R., Safdi, M.A., Lukasik, N.L., Huang, B., Haber, M.M. Arch. Intern. Med. (2000) [Pubmed]
  13. Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat. Kuwayama, H., Matsuo, Y., Eastwood, G.L. Am. J. Med. (1991) [Pubmed]
  14. Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors. Pérez Pimiento, A.J., Prieto Lastra, L., Rodríguez Cabreros, M.I., González Sánchez, L.A., Mosquera, M.R., Cubero, A.G. J. Allergy Clin. Immunol. (2006) [Pubmed]
  15. Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats. Endo, H., Yoshida, H., Ohmi, N., Higuchi, S. Antimicrob. Agents Chemother. (2001) [Pubmed]
  16. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Tran, A., Rey, E., Pons, G., Pariente-Khayat, A., D'Athis, P., Sallerin, V., Dupont, C. Clin. Pharmacol. Ther. (2002) [Pubmed]
  17. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Furuta, T., Shirai, N., Watanabe, F., Honda, S., Takeuchi, K., Iida, T., Sato, Y., Kajimura, M., Futami, H., Takayanagi, S., Yamada, M., Ohashi, K., Ishizaki, T., Hanai, H. Clin. Pharmacol. Ther. (2002) [Pubmed]
  18. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Ko, J.W., Jang, I.J., Shin, J.G., Nam, S.K., Shin, S.G., Flockhart, D.A. Clin. Pharmacol. Ther. (1999) [Pubmed]
  19. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Kim, K.A., Shon, J.H., Park, J.Y., Yoon, Y.R., Kim, M.J., Yun, D.H., Kim, M.K., Cha, I.J., Hyun, M.H., Shin, J.G. Clin. Pharmacol. Ther. (2002) [Pubmed]
  20. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. Sohn, D.R., Kwon, J.T., Kim, H.K., Ishizaki, T. Clin. Pharmacol. Ther. (1997) [Pubmed]
  21. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Berstad, A.E., Hatlebakk, J.G., Maartmann-Moe, H., Berstad, A., Brandtzaeg, P. Gut (1997) [Pubmed]
  22. Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses. Bergmann, J.F., Chassany, O., Simoneau, G., Lemaire, M., Segrestaa, J.M., Caulin, C. Clin. Pharmacol. Ther. (1992) [Pubmed]
  23. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Langtry, H.D., Wilde, M.I. Drugs (1997) [Pubmed]
  24. An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Brunner, G., Arnold, R., Hennig, U., Fuchs, W. Aliment. Pharmacol. Ther. (1993) [Pubmed]
  25. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Richter, J.E., Campbell, D.R., Kahrilas, P.J., Huang, B., Fludas, C. Arch. Intern. Med. (2000) [Pubmed]
  26. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Graham, D.Y., Agrawal, N.M., Campbell, D.R., Haber, M.M., Collis, C., Lukasik, N.L., Huang, B. Arch. Intern. Med. (2002) [Pubmed]
  27. Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Hawkey, G.M., Cole, A.T., McIntyre, A.S., Long, R.G., Hawkey, C.J. Gut (2001) [Pubmed]
  28. Lansoprazole pharmacokinetics in subjects with various degrees of kidney function. Karol, M.D., Machinist, J.M., Cavanaugh, J.M. Clin. Pharmacol. Ther. (1997) [Pubmed]
  29. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Desta, Z., Zhao, X., Shin, J.G., Flockhart, D.A. Clinical pharmacokinetics. (2002) [Pubmed]
  30. Identification of the human P450 enzymes involved in lansoprazole metabolism. Pearce, R.E., Rodrigues, A.D., Goldstein, J.A., Parkinson, A. J. Pharmacol. Exp. Ther. (1996) [Pubmed]
  31. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. Curi-Pedrosa, R., Daujat, M., Pichard, L., Ourlin, J.C., Clair, P., Gervot, L., Lesca, P., Domergue, J., Joyeux, H., Fourtanier, G. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  32. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Laine, L., Estrada, R., Trujillo, M., Knigge, K., Fennerty, M.B. Ann. Intern. Med. (1998) [Pubmed]
  33. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Wong, W.M., Wong, B.C., Hung, W.K., Yee, Y.K., Yip, A.W., Szeto, M.L., Fung, F.M., Tong, T.S., Lai, K.C., Hu, W.H., Yuen, M.F., Lam, S.K. Gut (2002) [Pubmed]
  34. Influence of lansoprazole treatment on diazepam plasma concentrations. Lefebvre, R.A., Flouvat, B., Karolac-Tamisier, S., Moerman, E., Van Ganse, E. Clin. Pharmacol. Ther. (1992) [Pubmed]
WikiGenes - Universities